Genmab | GEN - Operating Profit

Stock Price
2,097.00
Daily Change
7.00 0.33%
Monthly
4.33%
Yearly
51.08%
Q1 Forecast
1,920.90

Genmab reported DKK360M in Operating Profit for its fiscal quarter ending in June of 2025.





Operating Profit Change Date
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Almirall EUR 43.02M 28.78M Jun/2025
Amarin USD -1.7M 8.47M Sep/2025
Amgen USD 4.43B 1.77B Sep/2025
argenx SE USD 349.97M 146.13M Sep/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Bayer EUR -543M 556M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Demant DKK 1.87B 471M Jun/2025
Exelixis USD 256.36M 42.78M Sep/2025
Fresenius Medical Care EUR 449.94M 18.94M Sep/2025
Galapagos EUR -41.67M 15.36M Sep/2025
Genmab DKK 360M 172M Jun/2025
GlaxoSmithKline GBP 2.79B 764M Sep/2025
GN Store Nord DKK 340M 121M Sep/2025
GRIFOLS EUR 352.11M 2.57M Sep/2025
Hikma Pharmaceutical USD 187M 95M Jun/2025
Insmed USD -261.35M 7.48M Sep/2025
Lonza CHF 430M 104M Dec/2024
Merck EUR 1.21B 180M Sep/2025
Novartis USD 4.5B 363M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
UCB EUR 1B 678M Dec/2024